GSK-3 Inhibitors and Tooth Repair: An Ethical Analysis

Hostiuc, Sorin; Perlea, Paula; Marinescu, Mihai; Dogaroiu, Catalin; Drima, Eduard

doi:10.3389/fphar.2018.01495

Cited by 3 publications

(3 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most treatment-associated adverse events have been categorized as mild-to-moderate and have consisted of headache, diarrhea, cough, nausea, elevated liver transaminases (GGT and ALT) and creatine and fatigue. In a 2013 pilot study, and a phase II study in 2014 reported by del Ser et al and Lovestone, et al, respectively, these adverse events were significant enough to result in a dropout rate of more than one-third of those enrolled in the trial [126][127][128]. So far, most studies utilizing 9-ING-41 and Tideglusib have been focused on Alzheimer's or cancer, although a number of studies utilizing Tideglusib have recently gotten underway to evaluate its use in amyotrophic lateral sclerosis (ALS) and myotonic dystrophy (https://clinicaltrials.gov/ct2/results?…”

Section: Discussionmentioning

confidence: 95%

Revisiting the Role of GSK3, A Modulator of Innate Immunity, in Idiopathic Inclusion Body Myositis

Piazzi

Bavelloni

Cenni

et al. 2021

Cells

View full text Add to dashboard Cite

Idiopathic or sporadic inclusion body myositis (IBM) is the leading age-related (onset >50 years of age) autoimmune muscular pathology, resulting in significant debilitation in affected individuals. Once viewed as primarily a degenerative disorder, it is now evident that much like several other neuro-muscular degenerative disorders, IBM has a major autoinflammatory component resulting in chronic inflammation-induced muscle destruction. Thus, IBM is now considered primarily an inflammatory pathology. To date, there is no effective treatment for sporadic inclusion body myositis, and little is understood about the pathology at the molecular level, which would offer the best hopes of at least slowing down the degenerative process. Among the previously examined potential molecular players in IBM is glycogen synthase kinase (GSK)-3, whose role in promoting TAU phosphorylation and inclusion bodies in Alzheimer’s disease is well known. This review looks to re-examine the role of GSK3 in IBM, not strictly as a promoter of TAU and Abeta inclusions, but as a novel player in the innate immune system, discussing some of the recent roles discovered for this well-studied kinase in inflammatory-mediated pathology.

show abstract

Section: Discussionmentioning

confidence: 95%

Revisiting the Role of GSK3, A Modulator of Innate Immunity, in Idiopathic Inclusion Body Myositis

Piazzi

Bavelloni

Cenni

et al. 2021

Cells

View full text Add to dashboard Cite

show abstract

“…Further, it is desirable for the drug delivery system to have a higher drug loading capacity that reduces the number of delivery vehicles [31]. Hostiuc et al [32], in 2019, raised concern about the systemic action of tideglusib and its introduction to endodontics and restorative procedures. Intra-dental application of tideglusib could cause increased release time, which could potentiate a significant local effect.…”

Section: Discussionmentioning

confidence: 99%

Evaluating the Effect of Tideglusib-Loaded Bioactive Glass Nanoparticles as a Potential Dentine Regenerative Material

et al. 2022

View full text Add to dashboard Cite

Dental pulp treatment is the least intrusive procedure currently available for preserving the vitality of the pulp. Several studies are underway to improve the bioactivity of pulp capping materials. Tideglusib isa potent anti-inflammatory, antioxidant, and a regenerative drug developed against Alzheimer’s disease and has been shown to be effective in the treatment of dental cavities. However, its bioactive properties encapsulated within the nanoparticles as a component of pulp capping material are largely unknown. In this study, tideglusib-loaded bioactive glass nanoparticles were synthesized (tideglusib-BgNPs) and mixed at various concentrations into the calcium silicate cement to testits physiomechanical and bioactivitiescompared with biodentine (control). The calcium silicate cement with 10wgt% tideglusib-BgNPs showed comparable physiomechanical properties to that of biodentine. Additionally, the assessment of cytotoxicity and bioactivity (cell proliferation, wound healing, and cell migration assays) showed increased bioactivity in terms of better wound healing, increased proliferation, and better migration of human dental pulp stem cells than biodentine. These findings suggest new opportunities to use tideglusib-BgNPs in pulp therapy.

show abstract

“…1 Glycogen synthase kinase-3 inhibitor have been studied as a potential therapeutic agents in depression, anxiety, schizophrenia, Alzheimer's disease, supranuclear palsy, fragile X syndrome, multiple sclerosis, Parkinson's disease, Huntington's disease, stroke, traumatic brain injury, spinocerebellar ataxia type 1, sepsis, asthma, arthritis, colitis, peritonitis and various types of cancers. 2 These drugs have the capacity to modulate human stem cells in vivo. Tideglusib, a glycogen synthase kinase-3 inhibitor, initially tested for its role in Alzheimer's disease and psychiatric disorders, has the potential to change the conventional treatment of dental caries owing to its property to regrow dentine to fill a void.…”

mentioning

confidence: 99%